{"disease":{"id":"locally-advanced-or-metastatic-kras-g12c-mutated-nsclc-with-a-pd-l1-expression-1-or-a-pd-l1-expression-1-and-an-stk11-co-mutation","name":"locally advanced or metastatic kras g12c mutated nsclc with a pd l1 expression 1 or a pd l1 expression 1 and an stk11 co mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05445843","title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":95,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}